Successful of Chemo-Free Treatment with Dasatinib and Blinatumomab in a Pediatric EBF1-PDGFRβ Positive Acute Lymphoblastic Leukemia

Autor: Petruzziello, Fara, Giagnuolo, Giovanna, Cazzaniga, Giovanni, Beneduce, Giuliana, Locatelli, Franco, Stellato, Pio, Fazio, Grazia, Mirabelli, Giuseppe, Menna, Giuseppe, Parasole, Rosanna
Zdroj: Blood; November 2018, Vol. 132 Issue: 1, Number 1 Supplement 1 p5213-5213, 1p
Abstrakt: Recently, a novel subgroup of B Cell Precursor (BCP) Acute Lymphoblastic Leukemia (ALL), called Philadelphia-like(Ph-like) ALL, has been described. This high-risk group, despite the absence of BCR-ABL1rearrangement, shows genomic abnormalities that result in aberrant expression of cytokine receptors genes or tyrosine-kinase-activating signaling. These patients are poor responder to conventional chemotherapy but potentially sensitive to Tyrosine-Kinase Inhibitors (TKIs).
Databáze: Supplemental Index